anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective: To investigate the auditory and speech abilities of children with congenital auditory neuropathy (AN) after cochlear implant (CI), and to analyze the role of genetic testing in predicting the postoperative outcomes of CI in AN patients. Methods: Fourteen children diagnosed with AN by audiological battery test and underwent CI surgery in Xijing Hospital of the Air Force Medical University from 2002 to 2021 were included in this study (9 males and 5 females), with an implantation age of (3.1±1.7) years (mean±standard deviation, the same as follows). The preoperative audiological results and deafness gene results were analyzed. Another 52 children with ordinary sensorineural hearing loss (SNHL) were selected as the control group (30 males and 22 females), with an implantation age of (2.2±0.9) years. The demographic factors such as age and gender were matched with those of the AN group. The modified Category Auditory Performance (CAP-Ⅱ) and Speech Intelligence Rate (SIR) were used to evaluate the development of postoperative auditory and speech abilities in two groups. The Mandarin Speech Test System was used to test the speech recognition rate of monosyllabic and disyllabic words and sentences. Matlab 2022 software was used to analyze the data. Results: The results of gene in 14 children with AN showed that 6 cases had OTOF gene mutations, 2 cases (siblings) were confirmed to have TNN gene mutations through whole exome sequencing, and the remaining 6 cases were not find any clear pathogenic gene mutations. All subjects underwent CI surgery with electrodes implanted into the cochlea smoothly, and there were no postoperative complications. After surgery, all AN children had improved auditory and speech abilities, but only 64% (9/14) of AN children with CI had auditory ability scores comparable to the control group of SNHL children (including 2 children with TNN gene mutations), and 36% (5/14) of AN children had lower scores than the control group of SNHL children.The average speech recognition rate of two children with TNN gene mutations was 86.5%, and of two children with OTOF gene mutations was 83.2%. Conclusions: AN children achieved varying degrees of auditory and speech abilities after CI, but the postoperative effects varied greatly. Some children achieved similar results as ordinary SNHL children, but there were still some children whose effects were worse than those of ordinary SNHL children. The postoperative efficacy of CI in two children with AN caused by TNN pathogenic genes were comparable to that of ordinary SNHL in children. Genetic testing had certain reference value for predicting the postoperative effect of CI in AN children.
A dry sheet material (1), e.g. of paper or plastics polymer, has a foraminous structure, and contains within and filling its foramina a solid material (4) having entrapped therein and dispersed therethoughout droplets (3) of a liquid, the solid material being rupturable by pressure or heat to release the entrapped liquid. The solid material may be gelatin, casein, polyvinyl alcohol or a mixture thereof. The droplets may be contained as an emulsion therein, or may be contained as cores in microcapsules (fig. 6, not shown). The sheet material may have a coating on one or each side, which may be protective, or may be impermeable to the liquid of the droplets, so causing it to emerge on the other side of the sheet only. The liquid may be dryable adhesive so that when the sheet is pressed onto one or between two other sheets or solid objects they can be caused to adhere. The droplets may comprise a colourless dye-stuff, e.g. crystal violet lactone, in a solvent, and the coating may contain a phenolic polymer so that on rupture of the solid material, the two are brought into contact and react to give a colour over the area pressed. If one reagent is encapsulated, the other may also be present in the foramina as droplets or solid particles, e.g. the capsules may contain an epoxy resin and the binder a catalyst, or the capsules may contain a dissolved dyestuff and the binder particles of clay. The foraminous sheet may be made on a Fourdrinier machine in which the wire has vertical pins arranged in the pattern to be produced, the length of the pins beng equal to or a little greater than the thickness of the paper. Alternatively finished paper or plastics sheet can be perforated mechanically, or particles of a material insoluble in the pulp can be incorporated and subsequently leached out or sublimed off. The mixture of solid material and liquid droplets may be applied by ordinary paper-coating techniques, on or off the machine, the web being carried over a bed to prevent egress of the mixture to the underside. A doctor blade may be set to leave a coating of the mixture, or so that the mixture fills the foramina but substantially none remains on the surface of the sheet.
A dentrifice comprises a water-soluble chlorophyll derivative and a polishing agent mixture including a calcium or magnesium phosphate or carbonate and a water-insoluble salt of a polymetaphosphoric acid, which may contain up to 4 per cent. of water-soluble polymeta phosphates.  The dentrifice contains 0.01 to 2.0 per cent. chlorophyll (based on pure chlorophyll derivative) and (a) for tooth pastes 50 to 60 per cent polishing agent (b) for tooth powders 95.5 to 98 per cent. polishing agent, is preferred. 5 to 50 per cent of the insoluble polymeta phosphate is replaced by the other polishing agents.  The dentrifice is buffered at pH 6 to 7.  Specified chlorophyll derivatives are chlorophyllins, isochlorophyllins, pheophorbides, phytochlorins and phytorhodins prepared from natural chlorophylls a and b e.g. sodium and potassium magnesium chlorophylls, sodium and potassium copper or iron chlorophyllins; chlorophyll extracts preferably of 70 to 100 per purity; chlorophyll preparations containing the sodium and potassium salt of the copper, magnesium or iron complexes of phytochlorin e and phytorhodin g. Preferred polymetaphosphoric acid salts are the water-insoluble alkali metal salts especially those of sodium or potassium e.g. Maddress salt and Kurrol's salt.  Specified essential polishing agents are calcium carbonate, magnesium carbonate, dicalcium phosphate, tricalcium phosphate, dimagnesium phosphate and trimagnesium phosphate.  Optional ingredients are (a) other polishing agents e.g. bentonite, kaolin, ground bone meal, calcium sulphate, alumina gel, pumice, silica, whiting, tin oxide, hydrated magnesia, magnesium trisilicate, magnesia and talc; the wetting agents e.g. soap, diglycol laurate, diglycol stearate, sulphonated alcohols e.g. sodium lauryl sulphate, sulphonated oils and glycostearin; (c) buffers; (d) flavouring and sweetening agents e.g. saccharin; (e) preservatives (f) oxygen releasers such as puborates; (g) binders such as gum acacia and tragacanth, Indian gum, Irish moss, agar agar starch, locust bean gum, silica gel, pectin, clays and petrolatum; and (h) carriers and softeners such as water, glycerin, ethyl alcohol, mineral oil, syrup, glucose, invert sugars, glycols and honey.  Specification 601,801 is referred to.
The invention concerns a method applied to a substance treated to exhibit a biological activity, for example a coagulating or anticoagulation activity. The treated substance has been obtained, from a source substance having the biological activity, after a treatment such that the treated substance does not contain any molecule of the source substance in significant amount. The treatment may consist in carrying out a high dilution process of the type used for producing homeopathic solutions or granules. The method is designed to diagnose potential alterations of the treated substance by external factors. It comprises the step which consists in: placing a reference substance sample in a zone (19) protected from external influence; subjecting a sample of the treated substance to external influence (20); comparing the results of the tests carried out using a biological control system respectively with the reference substance sample and the treated substance sample. Thus, if the results of the tests are different, the alterations of the treated substance by external influence (20) are demonstrated.
The study is a prospective observational study focused on monitoring the effects of various treatment options for acute coronary syndrome (ACS) patients by measuring serum neopterin levels. Serum neopterin is a marker for measuring macrophage activation. Prior studies have illustrated that there are elevated serum neopterin levels in ACS. The investigators' study focused on comparing different treatment arms with regard to their neopterin levels and correlating neopterin levels to the Thrombolysis in Myocardial Infarction (TIMI) risk score. Patients enrolled are those with ACS. Blood samples are drawn at presentation, and at 72 hours after admission, or at office visits and at 72 hours later. Neopterin levels are measured via a commercially available assay.
PURPOSE:To obtain an emulsifying/solubilizing agent having excellent hydrophilic nature and safty and being stable for heat and light by composing essentially of an ester of maltotriitol and a higher fatty acid. CONSTITUTION:An emulsifying/solubilizing agent is composed essentially of an ester obtained from maltotriitol having >=70% purity and a higher fatty acid. Surface-active agents having a wide range from high HLB to low HLB whose hydrophilic natures are high and low respectively can be obtained by adjusting the degree of esterification in a process. The agents having 4-19 HLB and the degree of esterification from mono-ester to hexa-ester are obtained. The emulsifying/solubilizing agent has an extremely high hydrophilic nature and excellent solubility in water. The agent is stable for heat and light and the browning isn't caused even if it is used for emulsification at a high temperature. Furthermore, its toxicity is very low and is extremely safe as a surface-active agent used for human body.
Subjects with 2 confirmed mutations in RSPH1, Radial Spoke Head Component 9 (RSPH9), Radial Spoke Head Component 4A (RSPH4a), or Dynein Axonemal Heavy Chain 11 (DNAH11). This group may also include subjects with mutations in newly identified genes that are associated with a milder clinical phenotype.
FIELD: radioisotopic diagnosis, pharmacy. SUBSTANCE: method involves preparing the colloidal solution of rhenium sulfide labeled with To-98m (KOPEH) and its binding with human serum albumin and saline solution up to the final albumin concentration 3.0-3.5% and volume activity 34-42 MBk in 1 ml. Binding the known preparation (KOPEH) with human serum albumin ensures to obtain preparation exhibiting the stable colloidal-opsonine links with carrier - human albumin molecules. The proposed preparation is released from "tissue depot" at the increased velocity as compared with that of the known one. Preparation shows the constant accumulation rate in lymphonodules. EFFECT: improved quality, enhanced lymphotropic property, decreased radiation loading.
The Wills Eye Health System (WEHS) proposes to conduct a pilot study to evaluate the feasibility and effectiveness of a telephone-based intervention to improve rates of follow-up exams in patients with glaucoma. The prospective, randomized, controlled trial entitled "Improving Access to Eye Care in Patients with Glaucoma" will utilize cohort data from 2013 electronic medical record information to reduce the gap between recommended and actual follow-up utilization of eye care services in glaucoma patients. Patients with glaucoma will be recruited from the Wills Eye Glaucoma clinic who were seen between 3/1/13 and 10/31/13. A recall list will be generated for patients who have scheduled follow-up appointments from 9/1/13 to 11/30/13. These patients will be randomly assigned to the "Usual Care" group or "Intervention" group. The primary outcome will be successful attendance at a follow-up appointment within an appropriate time frame. This intervention is based on a CDC funded project at Wills to improve access to eye care in patients with diabetes. Thus, this pilot study will test the efficacy of a telephone-based intervention to improve follow-up adherence in patients with glaucoma by improving access to eye care.
Asia remains vulnerable to new and emerging infectious diseases. Understanding how to improve next generation sequencing (NGS) use in pathogen surveillance is an urgent priority for regional health security. Here we developed a pathogen genomic surveillance assessment framework to assess capacity in low-resource settings in South and Southeast Asia. Data collected between June 2022 and March 2023 from 42 institutions in 13 countries showed pathogen genomics capacity exists, but use is limited and under-resourced. All countries had NGS capacity and seven countries had strategic plans integrating pathogen genomics into wider surveillance efforts. Several pathogens were prioritized for human surveillance, but NGS application to environmental and human-animal interface surveillance was limited. Barriers to NGS implementation include reliance on external funding, supply chain challenges, trained personnel shortages and limited quality assurance mechanisms. Coordinated efforts are required to support national planning, address capacity gaps, enhance quality assurance and facilitate data sharing for decision making.
The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
Trauma exposure significantly impacts sleep in children. Nightmares are common. Evidence-based therapies are superior to medications but may not always be available in acute settings. No FDA-approved medications exist for the treatment of trauma-related sleep disturbances in youth. The evidence-base for the use of medications is largely based on case reports, retrospective chart reviews, clinical opinion, and adult studies. This evidence is reviewed for a number of medications, including prazosin, trazodone, alpha-2 agonists, quetiapine, and others.
Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be "massed" in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 \<34, can decide with their therapist whether early cessation of therapy is appropriate.
The aim of this meta-analysis was to compare the effects of LRYGB and LSG on dyslipidemia. Studies comparing the effects of LRYGB and LSG on dyslipidemia with follow-up of 12 months or more were included. Twenty-four studies comprising seven RCTs and 17 comparative observational studies were included. Meta-analysis of RCTs (n=487) showed that improvement/resolution of dyslipidemia was better after LRYGB (68.5%, n=161/235) compared to LSG (48.4%, n=122/252). Patients undergoing LRYGB were more than twice as likely to experience improvement/resolution in dyslipidemia compared to those undergoing LSG (OR 2.28, 95% CI 1.21-4.29, p=0.010). Both LRGYB and LSG appears effective in improving dyslipidemia at >12 months after surgery; however, this improvement is more than twice higher after LRYGB compared to LSG.
VCD appears to be significantly more common among females. The episode of dyspnea underlies the paradoxical, intermittent adduction of the vocal cords during inspiration. Methacholine challenge testing combined with laryngoscopy is useful in differentiating vocal cord dysfunction from asthma during the asymptomatic period.

In one visit patients will be characterized with a questionnaire based on the ISAAC questionnaire. Furthermore, FeNO, eCO, skin prick testing and total serum IgE will be examined. The psychiatric condition of patients will be determined by CBCL/6-18 and YSR/11-18 behavior questionnaires. After initial fiberoptic laryngoscopy and pulmonary function testing, bronchoprovocation is performed using nebulized methacholine at increasing doses, until a 20% decline in the forced expiratory volume in 1 second is achieved (PD20FEV1). Each methacholine testing will be followed by a second laryngoscopy and pulmonary function testing. The visualization of paradoxical vocal cord motion during inspiration will be recorded.
DNA damage causes the mutations that are the principal source of genetic variation. DNA damage detection and repair mechanisms therefore play a determining role in generating the genetic diversity on which natural selection acts. Speciation, it is commonly assumed, occurs at a rate set by the level of standing allelic diversity in a population. The process of speciation is driven by a combination of two evolutionary forces: genetic drift and ecological selection. Genetic drift takes place under the conditions of relaxed selection, and results in a balance between the rates of mutation and the rates of genetic substitution. These two processes, drift and selection, are necessarily mediated by a variety of mechanisms guaranteeing genome stability in any given species. One of the outstanding questions in evolutionary biology concerns the origin of the widely varying phylogenetic distribution of biodiversity across the Tree of Life and how the forces of drift and selection contribute to shaping that distribution. The following examines some of the molecular mechanisms underlying genome stability and the adaptive radiations that are associated with biodiversity and the widely varying species richness and evenness in the different eukaryotic lineages.
INTRODUCTION: Central Neurocytoma (CN) is a rare, WHO grade 2 brain tumor that predominantly affects young adults. Gross total resection (GTR) is often curative for CNs, but the optimal treatment paradigm including incorporation of RT, following subtotal resection (STR) and for scarcer pediatric cases has yet to be established.
METHODS: Patients between 2001 and 2021 with a pathologic diagnosis of CN were reviewed. Demographic, treatment, and tumor characteristics were recorded. Recurrence free survival (RFS) and overall survival (OS) were calculated according to the Kaplan Meier-method. Post-RT tumor volumetric regression analysis was performed.
RESULTS: Seventeen adults (≥ 18 years old) and 5 children (< 18 years old) met the criteria for data analysis (n = 22). With a median follow-up of 6.9 years, there was no tumor-related mortality. Patients who received STR and/or had atypical tumors (using a cut-off of Ki-67 > 4%) experienced decreased RFS compared to those who received GTR and/or were without atypical tumors. RFS at 5 years for typical CNs was 67% compared to 22% for atypical CNs. Every pediatric tumor was atypical and 3/5 recurred within 5 years. Salvage RT following tumor recurrence led to no further recurrences within the timeframe of continued follow-up; volumetric analysis for 3 recurrent tumors revealed an approximately 80% reduction in tumor size.
CONCLUSION: We provide encouraging evidence that CNs treated with GTR or with RT after tumor recurrence demonstrate good long-term tumor control.
The invention discloses a surfactant-lauryl alcohol polyoxyethylene chemical ablation agent and a preparation method thereof. The surfactant-lauryl alcohol polyoxyethylene chemical ablation agent disclosed by the invention can be used for performing chemical ablation treatment on tumors. A surfactant selected by the invention is of a hydrophilic variety of which the hydrophile lipophile balance (HLB) value is greater than 10. The greater the HLB value is, the stronger the hydrophilia of the surfactant is. The surfactant-lauryl alcohol polyoxyethylene chemical ablation agent is prepared mainly from a certain amount of surfactant and sterile injection water, for example, the surfactant and the sterile injection water are prepared into 1 percent of lauryl alcohol polyoxyethylene injection. The lauryl alcohol polyoxyethylene injection disclosed by the invention is colorless, tasteless, nontoxic and non-irritant and has no side effects. During an operating process that medical personnel ablates the tumors of a patient by using the surfactant-lauryl alcohol polyoxyethylene chemical ablation agent, the risk that the personnel is injured or equipment is damaged by the splashing of the injection does not exist.
A major heat-stable shrimp allergen is characterized as a 34 kDa protein corresponding to shrimp tropomyosin. Two IgE binding epitopes of this allergen have the sequences FLAEEADRK (SEQ ID NO: 1) and MQQLENDLDQVQESLLK (SEQ ID NO: 2), respectively. Surprisingly, both antigenic and allergenic activities of the allergen were found to be associated with these two peptide fractions. A-a-id antibodies recognized this allergen as well as a homologous 34 kDa allergen from lobster, prawn and crab, indicating that these antibodies recognize major cross-reacting IgE binding epitopes common to crustacea. The two epitopes are useful in the diagnosis and/or treatment of allergies, particularly in the desensitization of individuals that are allergic to shrimp and other crustacea. Variants and subfragments of the two epitopes display allergenicity, as assessed by reaction with allergen-specific IgE obtained from shrimp-sensitive patients.
Skin is a major reservoir of pathogenic bacteria and intensive care unit patients are particularly vulnerable to variations in skin colonization and so to infections. These bacterial skin colonizations can contaminate other patients, nursing staff or even samples, but above all they are an endogenous source of infection of material. These bacterial skin colonizations hold therefore a major place in the responsibility of infections associated with care and can potentially affect the length of patient hospitalization. 2% Chlorhexidine Gluconate pads have already demonstrated a real efficacy in the sustainable reduction of central venous catheter-related bacteremias in adults and in children, probably through a reduction of cutaneous microbial colonization. However, this hypothesis remains to be confirmed.

Patients in the pediatric surgical intensive care unit of Necker-Enfants Malades hospital are minors, hospitalized in critical and continuous surgical surveillance unit, for all surgical specialties excluding cardiac surgery. The use of central venous catheters concerns approximately 60% of the hospitalization days identified each year. To control catheter-related bacteremias, all intensive care unit patients are subjected to a service protocol since 2015, which defines a mild soap daily wash in patients without central venous catheter and a wash with Chlorhexidine in patients with central venous catheter. Successive standardized samples will be carried out on the skin of the children submissive to both types of washes during their hospitalization in intensive care unit.
A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.